Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BUN5
UPID:
CC28B_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BUN5; A8K789; Q8TBV8
Background:
Coiled-coil domain-containing protein 28B plays a pivotal role in ciliogenesis, influencing cilia length through interaction with MAPKAP1/SIN1, independent of the mTORC2 complex. It also modulates mTORC2 assembly and function, potentially enhancing AKT1 phosphorylation, without affecting mTORC1 complex assembly and function.
Therapeutic significance:
Given its involvement in Bardet-Biedl syndrome, a condition marked by severe pigmentary retinopathy, obesity, and other systemic manifestations, understanding the role of Coiled-coil domain-containing protein 28B could open doors to potential therapeutic strategies.